Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XX.g

Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

Publications

Chandra A, Rao N, Malhotra KP

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia.

Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia 2020 Apr 27;; — 2020 Apr 27

Agaimy A, Brueckl V, Schmidt D, Krieg S, Ullrich E, Meidenbauer N

Tuberculous and non-tuberculous granulomatous lymphadenitis in patients receiving imatinib mesylate (glivec) for metastatic gastrointestinal stromal tumor.

Case reports in oncology 2013 Jan;6;134-42 — 2013 Jan — 134-42

Daniels JM, Vonk-Noordegraaf A, Janssen JJ, Postmus PE, van Altena R

Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia.

The European respiratory journal 2009 Mar;33;670-2 — 2009 Mar — 670-2